Griffith University researchers are on the brink of a technological breakthrough in vaccine development with a possible new vaccine modality.
FDA should embrace new ways of evaluating rare disease drugs, report argues
To increase the pace of rare disease drug approvals, the FDA should embrace nontraditional data, deploy new forms of analysis and be more open about